Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Publication | Closed Access

DOI

732

Citations

References

2020

Year

Matteo Bassetti, Roger Echols, Yuko Matsunaga, Mari Ariyasu, Yohei Doi, Ricard Ferrer, Thomas P. Lodise, Thierry Naas, Yoshihito Niki, David L. Paterson,

The Lancet Infectious Diseases

Antimicrobial SusceptibilityHealth SciencesCarbapenem-resistant Gram-negative BacteriaKlebsiella PneumoniaeAntimicrobial TherapyMicrobiologyInfection ControlAntimicrobial ChemotherapyMedicineClinical MicrobiologyAntimicrobial ResistanceAvailable TherapySerious InfectionsDrug Resistance